Logo

Whatariff.com

Global Tariffs, Categorized

🇺🇸 United States
🌍 Select Country
📦 Cell cultures, whether or not modified

Cell cultures, whether or not modified

HS Code:

📦

Overview

The 'Cell cultures, whether or not modified' category (HS Code: 300290) encompasses a variety of biological materials including human, animal, or microbial cell cultures used primarily in medical research, biotechnology, and pharmaceutical industries. These cultures are critical for the development of vaccines, therapeutic proteins, and diagnostic tools. The category includes both unmodified and genetically modified cell lines, reflecting their diverse applications in cutting-edge scientific research and industrial production.

Total Trade Volume

USD 2.5 billion

Data from 2022

Source

United Nations Comtrade Database

Tariff Analysis

Average Rate

5.2%

Highest Rate

15% (applied by certain developing countries)

Lowest Rate

0% (under free trade agreements like EU-US TTIP provisions)

Common Restrictions

  • Stringent biosafety regulations for genetically modified cultures
  • Import licenses required for specific pathogenic cultures
  • Quarantine and testing protocols for live cultures
  • Export controls on dual-use biological materials

Market Trends

Rising demand for cell cultures in biopharmaceuticals

Increased trade volume due to growing production of biologics and biosimilars, especially for monoclonal antibodies and vaccine development.

2021-2022

Advancements in gene editing technologies

Boost in trade for genetically modified cell cultures used in CRISPR and other gene therapy research applications.

2020-2022

Increased focus on personalized medicine

Growing imports of specialized human cell lines for tailored therapeutic solutions and precision medicine.

2019-2022

Recent Developments

EU Updates Biosafety Regulations

The European Union introduced stricter guidelines for the import of genetically modified cell cultures to ensure compliance with biosafety standards.

March 2023

Potential delays in trade flows to EU countries as exporters adapt to new certification requirements.

US-China Biotech Trade Agreement

A bilateral agreement was signed to facilitate the exchange of non-pathogenic cell cultures for research purposes, reducing tariff barriers.

July 2022

Expected increase in trade volume between the two countries, fostering collaborative research.

Global Vaccine Production Surge

Post-COVID-19 recovery efforts have led to a spike in demand for cell cultures used in vaccine manufacturing, particularly for mRNA technologies.

January 2022

Significant growth in export markets for countries with advanced biotech capabilities like the US and Germany.